Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria

For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. We recently reported that HCC patients with a low MoRAL (model to predict tumor recurrence after LDLT) score (≤ 314.8) have excellent treatment outcomes after...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Cho, Yuri, Lee, Jeong-Hoon, Lee, Dong Hyeon, Cho, Eun Ju, Yu, Su Jong, Yi, Nam-Joon, Lee, Kwang-Woong, Kim, Yoon Jun, Yoon, Jung-Hwan, Suh, Kyung-Suk
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564586/
https://ncbi.nlm.nih.gov/pubmed/28548930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17733
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky